title: Frequency of myopathy in patients receiving lovastatin.
abstract: Lovastatin (Mevacor) 20 mg is being considered for nonprescription availability. Because the most severe untoward consequence of therapy with any statin is rhabdomyolysis, the clinical data for lovastatin pertaining to this adverse event were reviewed. Evidence to date, based on almost 2 decades of experience, points to an extremely low risk for myopathy and rhabdomyolysis associated with lovastatin.
authors.affiliation: University of Oklahoma Health Science Center, Tulsa, Oklahoma, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Wortmann
authors.forename: Robert W
authors.initials: RW
authors.lastname: Tipping
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Levine
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Melin
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008148:Lovastatin / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies; D012206:Rhabdomyolysis / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D008148:Lovastatin